 VYNE Therapeutics Inc NASDAQ: VYNE has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disorder of the skin. In the preclinical model, pan-bromodomain and extra-terminal BET inhibitor VYN201 reduced the expression of. 